source
- EnGene's shares crash on updated pivotal bladder cancer dataEnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The Canadian biotech's…Endpoints · 3mo ago↗ source
- Are health insurers out of the woods after a tough 2025?Last year, health insurer after health insurer slashed or withdrew their profit outlooks after being sucker-punched by high medical costs. This year is shaping up ...Endpoints · 3mo ago↗ source
- Blackstone puts $250M into Anagram to tackle cystic fibrosis complicationBlackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on a little-known biotech seeking to drastically reduce the numb…